| Bioactivity | Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3]. | ||||||||||||
| Invitro | Pentoxifylline (0.1-50 mM; 24-48 hours) inhibits cell proliferation in a dose-dependent manner[3].Pentoxifylline (0.5 mM; 12-36 hours) increases apoptosis and decreases autophagy levels in MDA-MB-231 cells[3].Pentoxifylline (0.5 mM; 12-36 hours) induces autophagy in MDA-MB-231 cells[3].Pentoxifylline (0.5 mM; 24-48 hours) blocks cell cycle at the G0/G1 phase[3].Pentoxifylline results in high LC3-II/LC3-ratio[3]. Cell Proliferation Assay[3] Cell Line: | ||||||||||||
| Name | Pentoxifylline | ||||||||||||
| CAS | 6493-05-6 | ||||||||||||
| Formula | C13H18N4O3 | ||||||||||||
| Molar Mass | 278.31 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Pentoxifylline
CAS: 6493-05-6 F: C13H18N4O3 W: 278.31
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.